Early Notification and Brand Change Cetomacrogol with glycerol
As advised via PHARMAC Tender Results of 30 April 2019 there is to be a change in the listing and future sole supply of Cetomacrogol with glycerol
New listing from 1 October 2019
Cetomacrogol Crm 90% with glycerol 10% 500 ml OP Boucher Pharmacode TBA Schedule price $2.35
Cetomacrogol Crm 90% with glycerol 10% 500 ml OP Boucher Pharmacode TBA Schedule price $3.10
Sorbolene with glycerin Pharmacy Health 500 ml OP Pharmacode 2366819 Schedule price $2.82
Sorbolene with glycerin Pharmacy Health 1,000 ml OP Pharmacode 2366827 Schedule price $3.87
HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 March 2020.
Brand switch fee for Community Pharmacy not advised.
As of the date of this notification ProPharma / PWR cannot accept Sorbolene with glycerin Pharmacy Health for credit under any circumstances.
From 1 July 2019 community pharmacies dispensing Cetomacrogol with glycerin will need to support patients changing to the new brand and manage stock during the transition.
We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.
Benefit of staying with incumbent while stock remains available are minimal, but every cent counts:-
500 ml : – Average dispensing is 500 ml. Therefore 1 x Sorbolene with glycerin 500 ml @ $2.82 x 3% = $0.0846 plus $0.253 (pack fee) giving you $0.3376
Compared to $2.35 x 3% = $0.0705 plus $0.253 (pack fee) giving you $0.3235
1,000 m l : – Average dispensing is 1,000 ml. Therefore 1 x Sorbolene with glycerin @ $3.87 x 3% = $0.1161 plus $0.253(pack fee) giving you $0.3691
Compared to $3.10 x 3% = $0.0930 plus $0.253 (pack fee) giving you $0.3460
You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 March 2020. Failure to do so may prove very costly.
Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.
ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 March 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.
Together we can make this a seamless and painless transition.
We thank you in anticipation of your ongoing support.